ArticleRSC advances2021
Natural coumarins as potential anti-SARS-CoV-2 agents supported by docking analysis.
Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Utility of 3-(2-oxo-2H-chromen-3-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde in the synthesis of novel 1,3,4-thiadiazoles or 1,3-thiazoles and study their cytotoxic activity.Scientific reports · 2025Article
- Natural and Synthetic Coumarins as Potential Drug Candidates against SARS-CoV-2/COVID-19.Current medicinal chemistry · 2025Review
- Virucidal and cytotoxic properties of a natural honeybee hives-derived formulation suspended with marine plasma.Frontiers in cellular and infection microbiology · 2025Article
- Comprehensive review on COVID-19: etiology, pathogenicity, and treatment.Frontiers in medicine · 2025Review
- Coumarins and Hesperetin Inhibit Human Respiratory Syncytial Virus Infection.International journal of molecular sciences · 2024Article
- An Overview on the Synthesis of Lamellarins and Related Compounds with Biological Interest.Molecules (Basel, Switzerland) · 2024Review
- Drug repurposing of pyrazolotriazine derivatives as potential anti-SARS-CoV-2 agents: in vitro and in silico studies.BMC chemistry · 2024Article
- An Overview of the Synthesis of 3,4-Fused Pyrrolocoumarins of Biological Interest.Molecules (Basel, Switzerland) · 2024Review
- Synthesis, biofilm formation inhibitory, and inflammation inhibitory activities of new coumarin derivatives.Scientific reports · 2024Article
- Antiviral Effects of Secondary Metabolites fromPlants (Basel, Switzerland) · 2023Article
- Naturally occurring phenylethanoids and phenylpropanoids: antimalarial potential.RSC advances · 2023Article
- Plant Coumarins with Anti-HIV Activity: Isolation and Mechanisms of Action.International journal of molecular sciences · 2023Review
- Coronavirus Inhibitors Targeting nsp16.Molecules (Basel, Switzerland) · 2023Article
- SARS-CoV-2 main protease targeting potent fluorescent inhibitors: Repurposing thioxanthones.Turkish journal of chemistry · 2023Article
- A novel coumarin-triazole-thiophene hybrid: synthesis, characterization, ADMET prediction, molecular docking and molecular dynamics studies with a series of SARS-CoV-2 proteins.Journal of chemical sciences (Bangalore, India) · 2023Article
- Marine-Based Candidates as Potential RSK1 Inhibitors: A Computational Study.Molecules (Basel, Switzerland) · 2022Article
- Evaluation of antiviral activity ofRSC advances · 2022Article
- Efficient Synthesis of Fluorescent Coumarins and Phosphorous-Containing Coumarin-Type Heterocycles via Palladium Catalyzed Cross-Coupling Reactions.Molecules (Basel, Switzerland) · 2022Article
- An Overview on the Synthesis of Fused Pyridocoumarins with Biological Interest.Molecules (Basel, Switzerland) · 2022Review
- Phytochemicals with Chemopreventive Activity Obtained from the Thai Medicinal PlantInternational journal of molecular sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is a global pandemic first identified in China, causing severe acute respiratory syndrome. One of the therapeutic strategies for combating viral infections is the search for viral spike proteins as attachment inhibitors among natural compounds using molecular docking. This review aims at shedding light on the antiviral potential of natural products belonging to the natural-products class of coumarins up to 2020. Moreover, all these compounds were filtered based on ADME analysis to determine their physicochemical properties, and the best 74 compounds were selected. Using virtual-screening methods, the selected compounds were investigated for potential inhibition of viral main protease (Mpro), viral methyltransferase (nsp16/10 complex), viral recognition binding domain (RBD) of S-protein, and human angiotensin-converting enzyme 2 (ACE2), which is the human receptor for viral S-protein targets, using molecular-docking studies. Promising potential results against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) and methyltransferase (nsp16) are presented.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.